Quantifying concordant genetic effects of de novo mutations on multiple disorders

  1. Hanmin Guo
  2. Lin Hou
  3. Yu Shi
  4. Sheng Chih Jin
  5. Xue Zeng
  6. Boyang Li
  7. Richard Lifton
  8. Martina Brueckner
  9. Hongyu Zhao  Is a corresponding author
  10. Qiongshi Lu  Is a corresponding author
  1. Tsinghua University, China
  2. Yale University, United States
  3. Washington University in St. Louis, United States
  4. Rockefeller University, United States
  5. University of Wisconsin-Madison, United States

Abstract

Exome sequencing on tens of thousands of parent-proband trios has identified numerous deleterious de novo mutations (DNMs) and implicated risk genes for many disorders. Recent studies have suggested shared genes and pathways are enriched for DNMs across multiple disorders. However, existing analytic strategies only focus on genes that reach statistical significance for multiple disorders and require large trio samples in each study. As a result, these methods are not able to characterize the full landscape of genetic sharing due to polygenicity and incomplete penetrance. In this work, we introduce EncoreDNM, a novel statistical framework to quantify shared genetic effects between two disorders characterized by concordant enrichment of DNMs in the exome. EncoreDNM makes use of exome-wide, summary-level DNM data, including genes that do not reach statistical significance in single-disorder analysis, to evaluate the overall and annotation-partitioned genetic sharing between two disorders. Applying EncoreDNM to DNM data of nine disorders, we identified abundant pairwise enrichment correlations, especially in genes intolerant to pathogenic mutations and genes highly expressed in fetal tissues. These results suggest that EncoreDNM improves current analytic approaches and may have broad applications in DNM studies.

Data availability

The current manuscript is a computational study, so no data have been generated for this manuscript.

The following previously published data sets were used

Article and author information

Author details

  1. Hanmin Guo

    Center for Statistical Science, Tsinghua University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Lin Hou

    Center for Statistical Science, Tsinghua University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Yu Shi

    Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Sheng Chih Jin

    Department of Genetics, Washington University in St. Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Xue Zeng

    Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Boyang Li

    Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Richard Lifton

    Laboratory of Human Genetics and Genomics, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Martina Brueckner

    Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Hongyu Zhao

    Yale University, New Haven, United States
    For correspondence
    Hongyu.Zhao@yale.edu
    Competing interests
    The authors declare that no competing interests exist.
  10. Qiongshi Lu

    Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, United States
    For correspondence
    qlu@biostat.wisc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4514-0969

Funding

National Science Foundation of China (No. 12071243)

  • Lin Hou

Shanghai Municipal Science and Technology Major Project (No. 2017SHZDZX01)

  • Lin Hou

Wisconsin Alumni Research Foundation

  • Qiongshi Lu

Waisman Center pilot grant program at University of Wisconsin-Madison

  • Qiongshi Lu

National Institutes of Health (No. R03HD100883 and R01GM134005)

  • Hongyu Zhao

National Science Foundation (DMS 1902903)

  • Hongyu Zhao

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Guo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 986
    views
  • 197
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Hanmin Guo
  2. Lin Hou
  3. Yu Shi
  4. Sheng Chih Jin
  5. Xue Zeng
  6. Boyang Li
  7. Richard Lifton
  8. Martina Brueckner
  9. Hongyu Zhao
  10. Qiongshi Lu
(2022)
Quantifying concordant genetic effects of de novo mutations on multiple disorders
eLife 11:e75551.
https://doi.org/10.7554/eLife.75551

Share this article

https://doi.org/10.7554/eLife.75551

Further reading

    1. Genetics and Genomics
    Yi Li, Long Gong ... Shangbang Gao
    Research Article

    Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.

    1. Genetics and Genomics
    Minsoo Noh, Xiangguo Che ... Sihoon Lee
    Research Article

    Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.